DATA SHEET. Biological Activity: Vif Binding assays pending.

Transcription

1 Proteins

2 APOBEC >> All

3 DATA SHEET Reagent: Recombinant Human APOBEC3F(E. coli) Catalog Number: Lot Number: Release Category: A Provided: 1mg/ml. Mass/vial: 50µg Diluent: PBS, 0.1% Sarcosyl. Special Characteristics: This protein binds to anti-cem15 murine monoclonal antibodies and rabbit polyclonal antibodies as determined by ELISA and Western. Biological Activity: Vif Binding assays pending. Molecular Weight: Approximately 46kD. Purity: >95% purity as determined by SDS-PAGE, reduced. Recommended Storage: -75 C Contributor: DAIDS, NIAID (Produced by ImmunoDiagnostics, Inc.) NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH from Immunodiagnostics: Recombinant Human APOBEC3F (E.coli)." REV: 06/24/2018 Page 1 of 1

4 DATA SHEET Reagent: Recombinant Human APOBEC3B(E. coli) Catalog Number: Lot Number: Release Category: A Provided: 1mg/ml. Mass/vial: 50 μg. Diluent: PBS, 0.1% Sarcosyl. Special Characteristics: This protein binds to anti-cem15 murine monoclonal antibodies and rabbit polyclonal antibodies as determined by Elisa and Western Elisa. Biological Activity: Vif Binding assays pending. Molecular Weight: Approximately 46kD. Purity: >95% Recommended Storage: -75 C Contributor: ImmunoDiagnostics, Inc. NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH from Immunodiagnostics: Recombinant Human APOBEC3B (E.coli)". REV: 06/24/2018 Page 1 of 1

5 DATA SHEET Reagent: Recombinant Human APOBEC3G (CEM15, E. coli.) Catalog Number: Lot Number: Release Category: A Provided: 100ug (diluted in PBS, 0.02% SDS) Description: Produced in the E.coli Expression System as a hexa-his fusion protein. Thrombin cleavage site at N-terminus may be used to derive CEM15 free of hexa-his sequence. Special Characteristics: This protein binds anti-cem15 murine monoclonal antibodies and rabbit polyclonal antibodies as determined by ELISA and Western Blot. Applications: Vif binding assays Molecular Weight: Approximately 44 kd. Purity: >95% purity as determined by SDS-PAGE Recommended Storage: -80 C Contributor: Immunodiagnostics, Inc. NOTE: Acknowledgement for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Cat#10067, Human APOBEC3G (CEM15) from Immunodiagnostics." REV: 06/24/2018 Page 1 of 1

6 DATA SHEET Reagent: Human APOBEC3G Recombinant Protein Catalog Number: Lot Number: Release Category: A Provided: 100 µg of purified protein at 1 mg/ml, in 50 mm Hepes, ph 8.0, M NaCl, 10 mm MgCl 2, 0.2 mm BMe, 5% Glycerol Description: A full length protein derived from Human APOBEC3G Special Characteristics: This protein is produced in a baculovirus expression system and purified by Ni-affinity chromatography. It contains a 4-His tag at the C-terminus. This protein binds to anti-apobec3g murine monoclonal antibodies and rabbit polyclonal antibodies as determined by ELISA and Western blot assays. It also binds to recombinant HIV-1 vif as determined by ELISA and Western Blot, and complexes with native vif in HIV-1 viral lysates. Sequence: Not Provided Applications: ELISA, Western Blot Molecular Weight: Approximately 44 kda not including the tag Purity: >98% by SDS-PAGE, reduced Recommended Storage: Keep the reagent at -80 C. Avoid freeze-thaw cycles as reagent degradation may result. Contributor: NIAID, DAIDS (Produced by ImmunoDX, LLC.) REV: 06/24/2018 Page 1 of 2

7 NOTE: Acknowledgment for publications should read The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Human APOBEC3G Recombinant Protein from ImmunoDX, LLC." REV: 06/24/2018 Page 2 of 2

8 DATA SHEET Reagent: scd4-183 (2-domain) Catalog Number: 7356 Lot Number: Release Category: C Provided: mg, 6.22 mg/ml. Storage buffer undetermined. Purity, >95%. Special Characteristics: First 2 domains of human CD4. Produced in E. coli, solubilized from inclusion bodies, refolded and purified. Binds to gp120, neutralizes HIV infection (lab adapted strains). Molecular Weight: 26 kda. Recommended Storage: -70 C Contributor: Pharmacia, Inc. References: Garlick RL, Kirschner RJ, Eckenrode FM, Tarpley WG, Tomich CS. Escherichia coli expression, purification, and biological activity of a truncated soluble CD4. AIDS Res Hum Retroviruses 6: , NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: scd4-183 from Pharmacia, Inc." Also include the reference cited above in any publications. Progenics Inc. currently holds and exclusive license for this material. This reagent is strictly limited to one aliquot per lab; however repeat requests will be honored on a case-by-case basis. To be considered, please submit the following form with your order request: Request for Additional Aliquots of scd4-183 REV: 06/24/2018 Page 1 of 2

9 REV: 06/24/2018 Page 2 of 2

10 DATA SHEET Reagent: Human Soluble CD4 Recombinant Protein (scd4) Catalog Number: 4615 Lot Number: Release Category: E Provided: 100 µg of purified protein at 1.0 mg/ml in 50 mm MES, 350 mm NaCl, ph 6.0. Description: Full-length extracellular domain of human CD4 (amino acids 1-370) produced in mammalian (CHO) expression system. Special Characteristics: Reactive with HIV-1 gp120 and anti-cd4 monoclonal and polyclonal antibodies. Its glycosylation pattern is identical to that of the natural human protein. Activity: Binds to HIV-1 gp120 and inhibits HIV-1 binding to and infection of CD4+ T lymphocytes. Molecular Weight: Runs at ~55 kda on reduced SDS-PAGE. Purity: >95% Recommended Storage: Keep at -80 C or lower. Avoid freeze-thaw cycles as reagent degradation may result. Contributor: Progenics Pharmaceuticals, Inc. NOTE: Acknowledgement for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Human Soluble CD4 Recombinant Protein (scd4) from Progenics." Not available to researchers at commercial organizations. Limited to one aliquot per lab. If additional material is needed, please contact Dr. Ozzie Dalia at Progenics: odalia@progenics.com. Recipient must not use or incorporate the reagent for commercial purposes. REV: 06/24/2018 Page 1 of 2

11 Recipient must not use or incorporate the reagent for commercial purposes. REV: 06/24/2018 Page 2 of 2

12 DATA SHEET Reagent: Human CD4-Ig Recombinant Protein Catalog Number: Lot Number: Release Category: C Provided: 250 μg of purified protein at 1.00 mg/ml in PBS buffer, ph 7.2, sterile filtered. Endotoxin= 0.1 EU/mg by LAL method Description: A full length protein derived from human CD4-Ig. Special Characteristics: This receptor protein is produced in a Expi293F expression system and purified by one-step purification by Protein A CIP column. Sequence: Protein sequence Purity: 87.72% by HPLC Recommended Storage: Keep at 4 C for short term storage and -80 C for long term storage. Avoid freeze-thaw cycles as reagent degradation may result. Contributor: Dr. Xueling Wu References: M. Jia, H. Lu, M. Markowitz, C. Cheng-Mayer and X. Wu. (2016). Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques. J Virol, 90(8), doi: /jvi PUBMED REV: 06/24/2018 Page 1 of 2

13 NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Human CD4-Ig Recombinant Protein from Dr. Xueling Wu." Also include the references cited above in any publications. Scientists at for-profit institutions or who intend commercial use of this reagent must contact the Rockefeller Office of Technology Transfer at the following address: REV: 06/24/2018 Page 2 of 2

14 DATA SHEET Reagent: CD4-IgG2 Catalog Number: Lot Number: Release Category: E Provided: 100 µl purified protein in PBS, at 1mg/mL. Description: CD4-IgG2 is a tetrameric fusion protein comprising human IgG2 in which the Fv portions of both heavy and light chains have been replaced by the V1 and V2 domains of human CD4. This biological material is cell culture derived and produced within a pharmaceutical production facility. It contains no animal material or blood product, and is a non-infectious and non-hazardous reagent. Special Characteristics: Applications: Inhibition of HIV infection, binding and detection of HIV envelope proteins. Purity: >95% by SDS PAGE and SE HPLC. Recommended Storage: -70 C Contributor: Progenics Pharmaceuticals, Inc. NOTE: Acknowledgement for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Cat#11780, CD4-IgG2 from Progenics Pharmaceuticals. Limited to one aliquot per lab. If additional material is needed, please contact Dr. Ozzie Dalia at Progenics: odalia@progenics.com Recipient must not use or incorporate the reagent for commercial purposes. REV: 06/24/2018 Page 1 of 2

15 Recipient must not use or incorporate the reagent for commercial purposes. REV: 06/24/2018 Page 2 of 2

16 Griffithsin (GRFT) >>

17 DATA SHEET Reagent: Red Alga Griffithsia sp. Griffithsin Recombinant Protein Catalog Number: Lot Number: Release Category: C Provided: 0.5 ml aliquots of a 1 mg/ml solution of GRFT in 50mM sodium phosphate buffer containing 300mM sodium chloride and 0.01% sodium azide (ph = 7.0). Description: Recombinant His-tagged GRFT, a non-glycosylated protein, was produced in E.coli. The protein is active against HIV-1, HIV-2, SIV and the SARS coronavirus. GRFT has been shown to be directly virucidal and prevents viral fusion and entry via direct association with oligosaccharides present on HIV gp120 and gp41 (Mori et al., 2005). The protein has been fully sequenced and its three-dimensional structure both his-tagged and native has been determined (Ziólkowska et al. 2006). The structure of GRFT bound to specific oligosaccharides has also been determined (Ziólkowska et al. 2007). GRFT is stable to multiple freeze-thaw cycles, organic solvents, room temperature and is stable >3 yrs at the suggested storage temperature. Special Characteristics: GRFT is active against most strains of HIV-1 as well as HIV-2 and SIV (Mori et al., 2005). The provided sample has been tested directly against HIV-1RF in a whole lymphoblastic cell assay system for HIV-1 induced cytopathicity which resulted in an EC50 = 0.15nM. Molecular Weight: Monomeric MW = 14,499 daltons (14.5 kda), GRFT is an obligate homo-dimer (dimer MW = 29 kda) in its native state. Purity: >95% pure as determined by SDS-PAGE analysis. Recommended Storage: -20 C Contributor: Drs. Barry O Keefe and James McMahon REV: 06/24/2018 Page 1 of 2

18 References: 1. Mori T, O'Keefe BR, Sowder RC 2nd, Bringans S, Gardella R, Berg S, Cochran P, Turpin JA, Buckheit RW Jr, McMahon JB, Boyd MR. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem. 280(10): , Emau P, Tian B, O'Keefe BR, Mori T, McMahon JB, Palmer KE, Jiang Y, Bekele G, Tsai CC. Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-hiv microbicide. J Med Primatol. 36(4-5):244-53, Ziólkowska NE, O'Keefe BR, Mori T, Zhu C, Giomarelli B, Vojdani F, Palmer KE, McMahon JB, Wlodawer A. Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding. Structure. 14(7): , Ziólkowska NE, Shenoy SR, O'Keefe BR, McMahon JB, Palmer KE, Dwek RA, Wormald MR, Wlodawer A. Crystallographic, thermodynamic, and molecular modeling studies of the mode of binding of oligosaccharides to the potent antiviral protein griffithsin. Proteins. 67(3):661-70, NOTE: Acknowledgment for publications should read The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Red Alga Griffithsia sp. Griffithsin Recombiant Protein from Drs. Barry O'Keefe and James McMahon. Also include the reference cited above in any publications. Strictly limited to one aliquot per lab. This reagent is patented by the U.S. Government. Additional supplies may require licensing agreement. Scientists at for-profit institutions, or who intend commercial use of this reagent must contact Dr. Sally H. Hu, Technology Licensing Specialist, NIH Office of Technology Transfer, 6011 Executive Boulevard, Suite 325, Rockville, MD , Tel: (301) , Fax: (301) , hus@mail.nih.gov, before the reagent can be released. REV: 06/24/2018 Page 2 of 2

19 DATA SHEET Reagent: Recombinant Human HEXIM1 Protein (E. coli) Catalog Number: Lot Number: Release Category: A Provided: 100 µg purified protein, in 50mM Tris, 0.1M NaCL, ph 7.7. Description: Full length human hexim1 gene expressed in the E.coli expression system. Special Characteristics: This protein binds hexim1 epitope specific rabbit polyclonal antibodies as determined by ELISA and Western ELISA. Hexim1 shows high binding activity for HIV-1 Tat (IIIB, MN, BaL) but not to BaL mutant Tat as determined by solid phase hexim1/tat/anti-tat mab-peroxidase sandwich ELISA and Western Blot assays. Applications: HIV-1 Tat binding assays, Immunization, Invivo Tat Inhibition assays (pending). Molecular Weight: 68 kd Purity: Purified by solvent extraction adn preparative SDS-PAGE, non-reduced, to 98% purity, as determined by SDS-PAGE, reduced. Recommended Storage: -70 C Contributor: Immunodiagnostics NOTE: Acknowledgement for publications should read The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Hexim1 protein, from Immunodiagnostics." REV: 06/24/2018 Page 1 of 2

20 REV: 06/24/2018 Page 2 of 2

21 HIV-1 >> ENV

22 DATA SHEET Reagent: HIV-1 RSC3 Δ371I/P363N Recombinant Protein Catalog Number: Lot Number: Release Category: C Provided: 200 µg of lyophilized protein. Add 1 ml of PBS, or less to obtain your desired concentration. Description: This protein was designed to preserve the antigenic structure of the CD4 binding site of gp120 while removing other antigenic regions. Resurfaced Stabilized Core 3 (RSC3) is based on the HXB2 Ds12F123 stabilized core. The double mutations bore on RSC3 Δ371I/P363N greatly diminishes the binding of CD4bs mabs to the protein, to an greater extent than RSC3 Δ371I. The variable regions 1-3 are removed. For more details, please see Wu et al Special Characteristics: Heavily glycosylated protein. Applications: CD4 binding site (CD4bs) antibody detection by ELISA. Molecular Weight: Appeared as a 65 KD protein (Calculated M.W. is 36.5 KD). Purity: >95% Recommended Storage: Stable at 4 C for at least one month. Aliquot and store at -80 C for long-term storage. Contributor: Drs. Zhi-Yong Yang, Peter Kwong, Gary Nabel and John Mascola REV: 06/24/2018 Page 1 of 2

23 References: Xueling Wu, Zhi-Yong Yang, Yuxing Li, et al: Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. Science, 329: (2010).Abstract Rebecca M. Lynch, Lillian Tran, Mark K. Louder, et al: The Development of CD4 Binding Site Antibodies during HIV-1 Infection.: The Development of CD4 Binding Site Antibodies during HIV-1 Infection J Virol July; 86(14): doi: /JVI Article. This article details the differences of binding between the 4 RSC3 proteins ARP offers and various broadly neutralizing antibodies. Please note Table 1 NOTE: Acknowledgment for publications should read The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 RSC3 Δ371I/P363N Recombinant Protein (Cat #12362) from Drs. Zhi-Yong Yang, Peter Kwong, Gary Nabel. Also include the references cited above in any publications. Scientists at for-profit institutions or who intend commercial use of this reagent must contact: The Office of Technology Development, NIAID, 6610 Rockledge Drive, Suite 2800, MSC 6606, Bethesda, MD, , Tel: , Fax: , before the reagent can be released. REV: 06/24/2018 Page 2 of 2

24 DATA SHEET Reagent: HIV-1 Resurfaced stabilized core Δ371I Recombinant Protein Catalog Number: Lot Number: Release Category: C Provided: 200 µg (0.177 ml) per vial at mg/ml in PBS. Description: This protein was designed to preserve the antigenic structure of the CD4 binding site of gp120 while removing other antigenic regions. Resurfaced Stabilized Core 3 (RSC3) is based on the HXB2 Ds12F123 stabilized core. The mutation bore on RSC3 Δ371I greatly diminishes the binding of CD4bs mabs to the protein. The variable regions 1-3 are removed. For more details, please see Wu et al Special Characteristics: Heavily glycosylated protein. Applications: CD4 binding site (CD4bs) antibody detection by ELISA. This protein is produced using the NIH-ARP HIV-1 RSC3?371I expression vector (cat# 12280). Alternative names: RSC3Δ371I Molecular Weight: Appeared as a 65 KD protein (Calculated M.W. is 36.5 KD). Purity: >95% Recommended Storage: Stable at 4 C for at least one month. Aliquot and store at -80 C for long-term storage. Contributor: Drs. Zhi-Yong Yang, Peter Kwong, Gary Nabel and John Mascola REV: 06/24/2018 Page 1 of 2

25 References: Xueling Wu, Zhi-Yong Yang, Yuxing Li, et al: Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. Science, 329: (2010).Abstract Rebecca M. Lynch, Lillian Tran, Mark K. Louder, et al: The Development of CD4 Binding Site Antibodies during HIV-1 Infection.: The Development of CD4 Binding Site Antibodies during HIV-1 Infection J Virol July; 86(14): doi: /JVI Abstract. This article details the differences of binding between the 4 RSC3 proteins ARP offers and various broadly neutralizing antibodies. Please note Table 1 NOTE: Acknowledgment for publications should read The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 RSC3 Δ371I Recombinant Protein from Drs. Zhi-Yong Yang, Peter Kwong, Gary Nabel (cat #12043). Also include the references cited above in any publications. Scientists at for-profit institutions or who intend commercial use of this reagent must contact the INSTITUTION AND/OR PROVIDER NAME at the following address: NIAIDAIDSReagent@niaid.nih.gov, before the reagent can be released. REV: 06/24/2018 Page 2 of 2

26 DATA SHEET Reagent: HIV-1 RSC3 G367R Recombinant Protein Catalog Number: Lot Number: Release Category: C Provided: 200 µg of lyophilized protein. Add 1 ml of PBS, or less to obtain your desired concentration. Description: This HXB2-based gp120 protein was designed to enhance CD4 binding site (CD4bs)-directed antibody binding. The G367R mutation maintains binding of strongly neutralizing mabs such as VRC01 while reducing binding of other CD4bs-mAbs. Special Characteristics: Resurfaced Stabilized Core 3 (RSC3) is based on the HXB2 Ds12F123 stabilized core. This protein lacks variable regions V1, V2, and V3, is truncated at the N- and C-terminal regions, and is cross-linked at different subregions to stabilize the structure. In ELISAs, it binds strongly to 2G12 and strong-moderately to VRC01, weakly to VRC03 and doesn't bind to b12. Alternate names: Resurfaced stabilized core G367R protein, RSC3 G367R Molecular Weight: Appeared as a 65 KD protein (Calculated M.W. is 36.5 KD). Purity: >95% Recommended Storage: Keep at -80 C. Avoid freeze-thaw cycles as reagent degradation may result. Contributor: Drs. Zhi-Yong Yang, Peter Kwong, Gary Nabel and John Mascola REV: 06/24/2018 Page 1 of 2

27 References: Wu X., Yang Z.Y., Li Y., et al: Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. Science, 329: (2010).Abstract Lynch R.M., Tran L., Louder M.K., et al: The Development of CD4 Binding Site Antibodies during HIV-1 Infection. J Virol July; 86(14): doi: /JVI Abstract. This article details the differences of binding between the 4 RSC3 proteins ARP offers and various broadly neutralizing antibodies. Please note Table 1. NOTE: Acknowledgment for publications should read The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 RSC3 G367R Recombinant Protein (Cat #12363) from Drs. Zhi-Yong Yang, Peter Kwong, Gary Nabel. Also include the references cited above in any publications. Scientists at for-profit institutions or who intend commercial use of this reagent must contact: The Office of Technology Development, NIAID, 6610 Rockledge Drive, Suite 2800, MSC 6606, Bethesda, MD, , Tel: , Fax: , before the reagent can be released. REV: 06/24/2018 Page 2 of 2

28 DATA SHEET Reagent: HIV-1 IIIB gp120 Recombinant Protein Catalog Number: Lot Number: Release Category: A Provided: 50 µg of purified protein in PBS. Description: A full length protein derived from HIV-1 IIIB gp120. Special Characteristics: This envelope protein is produced in a CHO expression system and purified by immunoaffinity chromatography. This protein binds to murine monoclonal antibodies of defined epitope specificity and human serum polyclonal antibodies in ELISA and Western ELISA. This protein binds to human T-cell receptor CD4 in ELISA and Western ELISA as determined by CD4/gp120/Anti-gp120 mab-peroxidase capture ELISA. This protein activates human T-Lymphocytes (CD4+, CD4-), in vitro, as measured by RNA synthesis during G0 to G1 transition phase of antigen-binding competent cells. Molecular Weight: Approximately 120 kda Purity: >98% by SDS-PAGE, reduced. Recommended Storage: Keep at -80 C. Avoid freeze-thaw cycles as reagent degradation may result. Contributor: NIAID, DAIDS (Produced by ImmunoDX, LLC.) REV: 06/24/2018 Page 1 of 2

29 NOTE: Acknowledgment for publications should read The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 IIIB gp120 Recombinant Protein from ImmunoDX, LLC. REV: 06/24/2018 Page 2 of 2

30 DATA SHEET Reagent: HIV-1 gp120 Recombinant Protein (AE.A244 D11gp120) Catalog Number: Lot Number: Release Category: C Provided: 50 μg of protein at 1.0 mg/ml in phosphate buffered saline, ph 7.4. Description: This CRFO1_AE Env gp120 subunit is derived from an individual chronically infected with HIV. The first 11 amino acids at the N-terminus of the mature Env protein have been deleted. Special Characteristics: This protein was produced in 293F cells by transient transfection, purified using lectin chromotography and filtered using 0.2 μm filtration. Protein sequences for Catalog numbers Purity: >90% as determined by reducing gel. Recommended Storage: -80 C. Contributor: Duke Human Vaccine Institute, Duke University Medical Center References: Liao, H. X., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., Kozink, D. M., Hwang, K. K., Chen, X., Tsao, C. Y., Liu, P., Lu, X., Parks, R. J., Montefiori, D. C., Ferrari, G., Pollara, J., Rao, M., Peachman, K. K., Santra, S., Letvin, N. L., Karasavvas, N., Yang, Z. Y., Dai, K., Pancera, M., Gorman, J., Wiehe, K., Nicely, N. I., Rerks-Ngarm, S., Nitayaphan, S., Kaewkungwal, J., Pitisuttithum, P., Tartaglia, J., Sinangil, F., Kim, J. H., Michael, N. L., Kepler, T. B., Kwong, P. D., Mascola, J. R., Nabel, G. J., Pinter, A., Zolla-Pazner, S. & Haynes, B. F. (2013). Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, REV: 06/24/2018 Page 1 of 2

31 Alam, S. M., Liao, H. X., Tomaras, G. D., Bonsignori, M., Tsao, C. Y., Hwang, K. K., Chen, H., Lloyd, K. E., Bowman, C., Sutherland, L., Jeffries, T. L., Jr., Kozink, D. M., Stewart, S., Anasti, K., Jaeger, F. H., Parks, R., Yates, N. L., Overman, R. G., Sinangil, F., Berman, P. W., Pitisuttithum, P., Kaewkungwal, J., Nitayaphan, S., Karasavva, N., Rerks-Ngarm, S., Kim, J. H., Michael, N. L., Zolla-Pazner, S., Santra, S., Letvin, N. L., Harrison, S. C. & Haynes, B. F. (2013). Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J Virol 87, NOTE: Acknowledgment for publications should read The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 gp120 Recombinant Protein (AE.A244 D11gp120) from Drs. Barton F. Haynes and Hua-Xin Liao. Also include the references cited above in any publication. REV: 06/24/2018 Page 2 of 2

32 DATA SHEET Reagent: HIV-1 Env V1V2 Recombinant Protein (AE.A244 V1V2.tags) Catalog Number: Lot Number: Release Category: C Provided: 1.0 mg/ml in phosphate buffered saline, ph 7.4. Description: This CRFO1_AE Env V1V2 subunit is derived from an individual chronically infected with HIV. It contains avi and histidine tags. Special Characteristics: This protein was produced in 293F cells by transient transfection, purified using nickel columns and filtered using 0.2 μm filtration. Protein sequences for Catalog numbers Purity: >90% as determined by reducing gel. Recommended Storage: -80 C. Contributor: Duke Human Vaccine Institute, Duke University Medical Center References: Liao, H. X., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., Kozink, D. M., Hwang, K. K., Chen, X., Tsao, C. Y., Liu, P., Lu, X., Parks, R. J., Montefiori, D. C., Ferrari, G., Pollara, J., Rao, M., Peachman, K. K., Santra, S., Letvin, N. L., Karasavvas, N., Yang, Z. Y., Dai, K., Pancera, M., Gorman, J., Wiehe, K., Nicely, N. I., Rerks-Ngarm, S., Nitayaphan, S., Kaewkungwal, J., Pitisuttithum, P., Tartaglia, J., Sinangil, F., Kim, J. H., Michael, N. L., Kepler, T. B., Kwong, P. D., Mascola, J. R., Nabel, G. J., Pinter, A., Zolla-Pazner, S. & Haynes, B. F. (2013). Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, REV: 06/24/2018 Page 1 of 2

33 protein variable regions 1 and 2. Immunity 38, NOTE: Acknowledgment for publications should read The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 Env V1V2 Recombinant Protein (AE.A244 V1V2.tags) from Drs. Barton F. Haynes and Hua-Xin Liao. Also include the references cited above in any publication. REV: 06/24/2018 Page 2 of 2

34 DATA SHEET Reagent: HIV-1 gp140 Recombinant Protein (B.6240 gp140c) Catalog Number: Lot Number: Release Category: C Provided: 50 μg of protein at 1.0 mg/ml in phosphate buffered saline, ph 7.4. Description: This subtype B Env gp140 subunit is derived from an individual acutely infected with HIV. The cleavage site between gp120 and gp41 has been mutated. Special Characteristics: This protein was produced in 293F cells by transient transfection, purified using lectin chromotography and filtered using 0.2 μm filtration. Protein sequences for Catalog numbers Purity: >90% on a reducing gel. Recommended Storage: -80 C. Contributor: Duke Human Vaccine Institute, Duke University Medical Center References: Liao, H. X., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., Kozink, D. M., Hwang, K. K., Chen, X., Tsao, C. Y., Liu, P., Lu, X., Parks, R. J., Montefiori, D. C., Ferrari, G., Pollara, J., Rao, M., Peachman, K. K., Santra, S., Letvin, N. L., Karasavvas, N., Yang, Z. Y., Dai, K., Pancera, M., Gorman, J., Wiehe, K., Nicely, N. I., Rerks-Ngarm, S., Nitayaphan, S., Kaewkungwal, J., Pitisuttithum, P., Tartaglia, J., Sinangil, F., Kim, J. H., Michael, N. L., Kepler, T. B., Kwong, P. D., Mascola, J. R., Nabel, G. J., Pinter, A., Zolla-Pazner, S. & Haynes, B. F. (2013). Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, Liao, H.X., Tsao, C. Y., Alam, S. M., Muldoon, M., Vandergrift, N., Ma, B. J., Lu, X., REV: 06/24/2018 Page 1 of 2

35 Liao, H.X., Tsao, C. Y., Alam, S. M., Muldoon, M., Vandergrift, N., Ma, B. J., Lu, X., Sutherland, L. L., Screarce, R.M., Bowman, C., Parks, R., Chen, H., Blinn, J.H., Lapedes, A., Watson, S., Xia, S.M. Foulger, A., Hahn, B. H., Shaw, G. M., Swanstrom, R., Montefiori, D. C., Gao, F., Haynes, B. F. & Kober, B. (2013). Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. J Virol 87, NOTE: Acknowledgment for publications should read The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 gp140 Recombinant Protein (B.6240 gp140c) from Drs. Barton F. Haynes and Hua-Xin Liao. Also include the references cited above in any publication. REV: 06/24/2018 Page 2 of 2

36 DATA SHEET Reagent: HIV-1 JRFL gp140 Recombinant Protein (B.JRFL gp140cf) Catalog Number: Lot Number: Release Category: C Provided: 50 μg of protein at 1.0 mg/ml in phosphate buffered saline, ph 7.4. Description: This subtype B Env gp140 subunit is derived from an individual chronically infected with HIV. The cleavage site between gp120 and gp41 and the fusion domain have been deleted. Special Characteristics: This protein was produced in 293F cells by transient transfection, purified using lectin chromotography and filtered using 0.2 μm filtration. Protein sequences for Catalog numbers Purity: >90% on a reducing gel. Recommended Storage: -80 C. Contributor: Duke Human Vaccine Institute, Duke University Medical Center References: Liao, H. X., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., Kozink, D. M., Hwang, K. K., Chen, X., Tsao, C. Y., Liu, P., Lu, X., Parks, R. J., Montefiori, D. C., Ferrari, G., Pollara, J., Rao, M., Peachman, K. K., Santra, S., Letvin, N. L., Karasavvas, N., Yang, Z. Y., Dai, K., Pancera, M., Gorman, J., Wiehe, K., Nicely, N. I., Rerks-Ngarm, S., Nitayaphan, S., Kaewkungwal, J., Pitisuttithum, P., Tartaglia, J., Sinangil, F., Kim, J. H., Michael, N. L., Kepler, T. B., Kwong, P. D., Mascola, J. R., Nabel, G. J., Pinter, A., Zolla-Pazner, S. & Haynes, B. F. (2013). Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, Liao, H.X., Tsao, C. Y., Alam, S. M., Muldoon, M., Vandergrift, N., Ma, B. J., Lu, X., REV: 06/24/2018 Page 1 of 2

37 Liao, H.X., Tsao, C. Y., Alam, S. M., Muldoon, M., Vandergrift, N., Ma, B. J., Lu, X., Sutherland, L. L., Screarce, R.M., Bowman, C., Parks, R., Chen, H., Blinn, J.H., Lapedes, A., Watson, S., Xia, S.M. Foulger, A., Hahn, B. H., Shaw, G. M., Swanstrom, R., Montefiori, D. C., Gao, F., Haynes, B. F. & Kober, B. (2013). Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. J Virol 87, NOTE: Acknowledgment for publications should read The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 JRFL gp140 Recombinant Protein (B.JRFL gp140cf) from Drs. Barton F. Haynes and Hua-Xin Liao. Also include the references cited above in any publication. REV: 06/24/2018 Page 2 of 2

38 DATA SHEET Reagent: HIV-1 gp140 Recombinant Protein (B.9021 gp140c) Catalog Number: Lot Number: Release Category: C Provided: 50 μg of protein at 1.0 mg/ml in phosphate buffered saline, ph 7.4. Description: This subtype B Env gp140 subunit is derived from an individual acutely infected with HIV. The cleavage site between gp120 and gp41 was mutated. Special Characteristics: This protein was produced in 293F cells by transient transfection, purified using lectin chromotography and filtered using 0.2 μm filtration. Protein sequences for Catalog numbers Purity: >90% on a reducing gel. Recommended Storage: -80 C. Contributor: Duke Human Vaccine Institute, Duke University Medical Center References: Liao, H. X., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., Kozink, D. M., Hwang, K. K., Chen, X., Tsao, C. Y., Liu, P., Lu, X., Parks, R. J., Montefiori, D. C., Ferrari, G., Pollara, J., Rao, M., Peachman, K. K., Santra, S., Letvin, N. L., Karasavvas, N., Yang, Z. Y., Dai, K., Pancera, M., Gorman, J., Wiehe, K., Nicely, N. I., Rerks-Ngarm, S., Nitayaphan, S., Kaewkungwal, J., Pitisuttithum, P., Tartaglia, J., Sinangil, F., Kim, J. H., Michael, N. L., Kepler, T. B., Kwong, P. D., Mascola, J. R., Nabel, G. J., Pinter, A., Zolla-Pazner, S. & Haynes, B. F. (2013). Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, Liao, H. X., Tsao, C. Y., Alam, S. M., Muldoon, M., Vandergrift, N., Ma, B. J., Lu, X., REV: 06/24/2018 Page 1 of 2

39 Liao, H. X., Tsao, C. Y., Alam, S. M., Muldoon, M., Vandergrift, N., Ma, B. J., Lu, X., Sutherland, L. L., Screarce, R.M., Bowman, C., Parks, R., Chen, H., Blinn, J.H., Lapedes, A., Watson, S., Xia, S.M. Foulger, A., Hahn, B. H., Shaw, G. M., Swanstrom, R., Montefiori, D. C., Gao, F., Haynes, B. F. & Kober, B. (2013). Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. J Virol 87, NOTE: Acknowledgment for publications should read The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 gp140 Recombinant Protein (B.9021 gp140c) from Drs. Barton F. Haynes and Hua-Xin Liao. Also include the references cited above in any publication. REV: 06/24/2018 Page 2 of 2

40 DATA SHEET Reagent: HIV-1 gp120 Recombinant Protein (B.9021 D11gp120) Catalog Number: Lot Number: Release Category: C Provided: 50 μg of protein at 1.0 mg/ml in phosphate buffered saline, ph 7.4. Description: This subtype B Env gp120 subunit is derived from an individual chronically infected with HIV. The first 11 amino acids at the N-terminus of the mature Env protein have been deleted. Special Characteristics: This protein was produced in 293F cells by transient transfection, purified using lectin chromotography and filtered using 0.2 μm filtration. Protein sequences for Catalog numbers Purity: >90% on a reducing gel. Recommended Storage: -80 C. Contributor: Duke Human Vaccine Institute, Duke University Medical Center References: Liao, H. X., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., Kozink, D. M., Hwang, K. K., Chen, X., Tsao, C. Y., Liu, P., Lu, X., Parks, R. J., Montefiori, D. C., Ferrari, G., Pollara, J., Rao, M., Peachman, K. K., Santra, S., Letvin, N. L., Karasavvas, N., Yang, Z. Y., Dai, K., Pancera, M., Gorman, J., Wiehe, K., Nicely, N. I., Rerks-Ngarm, S., Nitayaphan, S., Kaewkungwal, J., Pitisuttithum, P., Tartaglia, J., Sinangil, F., Kim, J. H., Michael, N. L., Kepler, T. B., Kwong, P. D., Mascola, J. R., Nabel, G. J., Pinter, A., Zolla-Pazner, S. & Haynes, B. F. (2013). Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, REV: 06/24/2018 Page 1 of 2

41 protein variable regions 1 and 2. Immunity 38, NOTE: Acknowledgment for publications should read The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 gp120 Recombinant Protein (B.9021 D11gp120) from Drs. Barton F. Haynes and Hua-Xin Liao. Also include the references cited above in any publication. REV: 06/24/2018 Page 2 of 2

42 DATA SHEET Reagent: HIV-1 gp120 Recombinant Protein (C.1086 D7gp120K160N) Catalog Number: Lot Number: Release Category: C Provided: 50 μg of protein at 1.0 mg/ml in phosphate buffered saline, ph 7.4. Description: This subtype C Env gp120 subunit is derived from an individual acutely infected with HIV. The first 7 amino acids at the N-terminus of the mature Env protein have been deleted and the lysine at position 160 has been changed to asparagine. Special Characteristics: This protein was produced in 293F cells by transient transfection, purified using lectin chromotography and filtered using 0.2 μm filtration. Protein sequences for Catalog numbers Purity: >90% on a reducing gel. Recommended Storage: -80 C. Contributor: Duke Human Vaccine Institute, Duke University Medical Center References: Liao, H. X., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., Kozink, D. M., Hwang, K. K., Chen, X., Tsao, C. Y., Liu, P., Lu, X., Parks, R. J., Montefiori, D. C., Ferrari, G., Pollara, J., Rao, M., Peachman, K. K., Santra, S., Letvin, N. L., Karasavvas, N., Yang, Z. Y., Dai, K., Pancera, M., Gorman, J., Wiehe, K., Nicely, N. I., Rerks-Ngarm, S., Nitayaphan, S., Kaewkungwal, J., Pitisuttithum, P., Tartaglia, J., Sinangil, F., Kim, J. H., Michael, N. L., Kepler, T. B., Kwong, P. D., Mascola, J. R., Nabel, G. J., Pinter, A., Zolla-Pazner, S. & Haynes, B. F. (2013). Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, REV: 06/24/2018 Page 1 of 2

43 Alam, S. M., Liao, H. X., Tomaras, G. D., Bonsignori, M., Tsao, C. Y., Hwang, K. K., Chen, H., Lloyd, K. E., Bowman, C., Sutherland, L., Jeffries, T. L., Jr., Kozink, D. M., Stewart, S., Anasti, K., Jaeger, F. H., Parks, R., Yates, N. L., Overman, R. G., Sinangil, F., Berman, P. W., Pitisuttithum, P., Kaewkungwal, J., Nitayaphan, S., Karasavva, N., Rerks-Ngarm, S., Kim, J. H., Michael, N. L., Zolla-Pazner, S., Santra, S., Letvin, N. L., Harrison, S. C. & Haynes, B. F. (2013). Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J Virol 87, NOTE: Acknowledgment for publications should read The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 gp120 Recombinant Protein (C.1086 D7gp120K160N) from Drs. Barton F. Haynes and Hua-Xin Liao. Also include the references cited above in any publication. REV: 06/24/2018 Page 2 of 2

44 DATA SHEET Reagent: HIV-1 gp120 Recombinant Protein (C.1086 D7gp120) Catalog Number: Lot Number: Release Category: C Provided: 50 μg of protein at 1.0 mg/ml in phosphate buffered saline, ph 7.4. Description: This subtype C Env gp120 subunit is derived from an individual acutely infected with HIV. The first 7 amino acids at the N-terminus of the mature Env protein have been deleted. Special Characteristics: This protein was produced in 293F cells by transient transfection, purified using lectin chromotography and filtered using 0.2 μm filtration. Protein sequences for Catalog numbers Purity: >90% on a reducing gel. Recommended Storage: -80 C. Contributor: Duke Human Vaccine Institute, Duke University Medical Center References: Liao, H. X., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., Kozink, D. M., Hwang, K. K., Chen, X., Tsao, C. Y., Liu, P., Lu, X., Parks, R. J., Montefiori, D. C., Ferrari, G., Pollara, J., Rao, M., Peachman, K. K., Santra, S., Letvin, N. L., Karasavvas, N., Yang, Z. Y., Dai, K., Pancera, M., Gorman, J., Wiehe, K., Nicely, N. I., Rerks-Ngarm, S., Nitayaphan, S., Kaewkungwal, J., Pitisuttithum, P., Tartaglia, J., Sinangil, F., Kim, J. H., Michael, N. L., Kepler, T. B., Kwong, P. D., Mascola, J. R., Nabel, G. J., Pinter, A., Zolla-Pazner, S. & Haynes, B. F. (2013). Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, Alam, S. M., Liao, H. X., Tomaras, G. D., Bonsignori, M., Tsao, C. Y., Hwang, K. K., Chen, REV: 06/24/2018 Page 1 of 2

45 Alam, S. M., Liao, H. X., Tomaras, G. D., Bonsignori, M., Tsao, C. Y., Hwang, K. K., Chen, H., Lloyd, K. E., Bowman, C., Sutherland, L., Jeffries, T. L., Jr., Kozink, D. M., Stewart, S., Anasti, K., Jaeger, F. H., Parks, R., Yates, N. L., Overman, R. G., Sinangil, F., Berman, P. W., Pitisuttithum, P., Kaewkungwal, J., Nitayaphan, S., Karasavva, N., Rerks-Ngarm, S., Kim, J. H., Michael, N. L., Zolla-Pazner, S., Santra, S., Letvin, N. L., Harrison, S. C. & Haynes, B. F. (2013). Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J Virol 87, NOTE: Acknowledgment for publications should read The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 gp120 Recombinant Protein (C.1086 D7gp120) from Drs. Barton F. Haynes and Hua-Xin Liao. Also include the references cited above in any publication. REV: 06/24/2018 Page 2 of 2

46 DATA SHEET Reagent: HIV-1 gp140 Recombinant Protein (C.1086 gp140c K160N) Catalog Number: Lot Number: Release Category: C Provided: 50 μg of protein at 1.0 mg/ml in phosphate buffered saline, ph 7.4. Description: This subtype C Env gp140 subunit is derived from an individual acutely infected with HIV. The cleavage site between gp120 and gp41 has been mutated and the lysine at position 160 has been changed to asparagine. Special Characteristics: This protein was produced in 293F cells by transient transfection, purified using lectin chromotography and filtered using 0.2 μm filtration. Protein sequences for Catalog numbers Purity: >90% on a reducing gel. Recommended Storage: -80 C. Contributor: Duke Human Vaccine Institute, Duke University Medical Center References: Liao, H. X., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., Kozink, D. M., Hwang, K. K., Chen, X., Tsao, C. Y., Liu, P., Lu, X., Parks, R. J., Montefiori, D. C., Ferrari, G., Pollara, J., Rao, M., Peachman, K. K., Santra, S., Letvin, N. L., Karasavvas, N., Yang, Z. Y., Dai, K., Pancera, M., Gorman, J., Wiehe, K., Nicely, N. I., Rerks-Ngarm, S., Nitayaphan, S., Kaewkungwal, J., Pitisuttithum, P., Tartaglia, J., Sinangil, F., Kim, J. H., Michael, N. L., Kepler, T. B., Kwong, P. D., Mascola, J. R., Nabel, G. J., Pinter, A., Zolla-Pazner, S. & Haynes, B. F. (2013). Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, REV: 06/24/2018 Page 1 of 2

47 Liao, H.X., Tsao, C. Y., Alam, S. M., Muldoon, M., Vandergrift, N., Ma, B. J., Lu, X., Sutherland, L. L., Screarce, R.M., Bowman, C., Parks, R., Chen, H., Blinn, J.H., Lapedes, A., Watson, S., Xia, S.M. Foulger, A., Hahn, B. H., Shaw, G. M., Swanstrom, R., Montefiori, D. C., Gao, F., Haynes, B. F. & Kober, B. (2013). Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. J Virol 87, NOTE: Acknowledgment for publications should read The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 gp140 Recombinant Protein (C.1086 gp140c K160N) from Drs. Barton F. Haynes and Hua-Xin Liao. Also include the references cited above in any publication. REV: 06/24/2018 Page 2 of 2

48 DATA SHEET Reagent: HIV-1 gp120 Recombinant Protein (M.CON-S D11gp120) Catalog Number: Lot Number: Release Category: C Provided: 50 μg of protein at 1.0 mg/ml in phosphate buffered saline, ph 7.4. Description: This gp120 subunit Env is from the group M consensus sequence. The first 11 amino acids at the N-terminus of the matured Env protein have been deleted. Special Characteristics: This protein was produced in 293F cells by transient transfection, purified using lectin chromotography and filtered using 0.2 μm filtration. Protein sequences for Catalog numbers Purity: >90% on a reducing gel. Recommended Storage: -80 C. Contributor: Duke Human Vaccine Institute, Duke University Medical Center References: Liao, H. X., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., Kozink, D. M., Hwang, K. K., Chen, X., Tsao, C. Y., Liu, P., Lu, X., Parks, R. J., Montefiori, D. C., Ferrari, G., Pollara, J., Rao, M., Peachman, K. K., Santra, S., Letvin, N. L., Karasavvas, N., Yang, Z. Y., Dai, K., Pancera, M., Gorman, J., Wiehe, K., Nicely, N. I., Rerks-Ngarm, S., Nitayaphan, S., Kaewkungwal, J., Pitisuttithum, P., Tartaglia, J., Sinangil, F., Kim, J. H., Michael, N. L., Kepler, T. B., Kwong, P. D., Mascola, J. R., Nabel, G. J., Pinter, A., Zolla-Pazner, S. & Haynes, B. F. (2013). Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, Alam, S. M., Liao, H. X., Tomaras, G. D., Bonsignori, M., Tsao, C. Y., Hwang, K. K., Chen, REV: 06/24/2018 Page 1 of 2

49 Alam, S. M., Liao, H. X., Tomaras, G. D., Bonsignori, M., Tsao, C. Y., Hwang, K. K., Chen, H., Lloyd, K. E., Bowman, C., Sutherland, L., Jeffries, T. L., Jr., Kozink, D. M., Stewart, S., Anasti, K., Jaeger, F. H., Parks, R., Yates, N. L., Overman, R. G., Sinangil, F., Berman, P. W., Pitisuttithum, P., Kaewkungwal, J., Nitayaphan, S., Karasavva, N., Rerks-Ngarm, S., Kim, J. H., Michael, N. L., Zolla-Pazner, S., Santra, S., Letvin, N. L., Harrison, S. C. & Haynes, B. F. (2013). Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J Virol 87, NOTE: Acknowledgment for publications should read The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: M.CON-S D11gp120 from Drs. Barton F. Haynes and Hua-Xin Liao. Also include the references cited above in any publication. REV: 06/24/2018 Page 2 of 2

50 DATA SHEET Reagent: HIV-1 gp120 Recombinant Protein (B D11gp120 mutc) Catalog Number: Lot Number: Release Category: C Provided: 50 μg of protein at 1.0 mg/ml in phosphate buffered saline, ph 7.4. Description: This subtype B Env gp120 subunit is derived from an individual acutely infected with HIV. The first 11 amino acids at the N-terminus of the mature Env protein have been deleted and the site at the V3 loop sensitive to cleavage has been mutated. Special Characteristics: This protein was produced in 293F cells by transient transfection, purified using lectin chromotography and filtered using 0.2 μm filtration. Protein sequences for Catalog numbers Purity: >90% on a reducing gel. Recommended Storage: -80 C. Contributor: Duke Human Vaccine Institute, Duke University Medical Center References: Liao, H. X., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., Kozink, D. M., Hwang, K. K., Chen, X., Tsao, C. Y., Liu, P., Lu, X., Parks, R. J., Montefiori, D. C., Ferrari, G., Pollara, J., Rao, M., Peachman, K. K., Santra, S., Letvin, N. L., Karasavvas, N., Yang, Z. Y., Dai, K., Pancera, M., Gorman, J., Wiehe, K., Nicely, N. I., Rerks-Ngarm, S., Nitayaphan, S., Kaewkungwal, J., Pitisuttithum, P., Tartaglia, J., Sinangil, F., Kim, J. H., Michael, N. L., Kepler, T. B., Kwong, P. D., Mascola, J. R., Nabel, G. J., Pinter, A., Zolla-Pazner, S. & Haynes, B. F. (2013). Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, REV: 06/24/2018 Page 1 of 2

51 Alam, S. M., Liao, H. X., Tomaras, G. D., Bonsignori, M., Tsao, C. Y., Hwang, K. K., Chen, H., Lloyd, K. E., Bowman, C., Sutherland, L., Jeffries, T. L., Jr., Kozink, D. M., Stewart, S., Anasti, K., Jaeger, F. H., Parks, R., Yates, N. L., Overman, R. G., Sinangil, F., Berman, P. W., Pitisuttithum, P., Kaewkungwal, J., Nitayaphan, S., Karasavva, N., Rerks-Ngarm, S., Kim, J. H., Michael, N. L., Zolla-Pazner, S., Santra, S., Letvin, N. L., Harrison, S. C. & Haynes, B. F. (2013). Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J Virol 87, NOTE: Acknowledgment for publications should read The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 gp120 Recombinant Protein (B D11gp120 mutc) from Drs. Barton F. Haynes and Hua-Xin Liao. Also include the references cited above in any publication. REV: 06/24/2018 Page 2 of 2

52 DATA SHEET Reagent: HIV-1 gp140 Recombinant Protein (C.1086 gp140c) Catalog Number: Lot Number: Release Category: C Provided: 50 μg of protein at 1.0 mg/ml in phosphate buffered saline, ph 7.4. Description: This subtype C Env gp140 subunit is derived from an individual acutely infected with HIV. The cleavage site between gp120 and gp41 has been matuted. Special Characteristics: This protein was produced in 293F cells by transient transfection, purified using lectin chromotography and filtered using 0.2 μm filtration. Protein sequences for Catalog numbers Purity: >90% on a reducing gel. Recommended Storage: -80 C. Contributor: Duke Human Vaccine Institute, Duke University Medical Center References: Liao, H. X., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., Kozink, D. M., Hwang, K. K., Chen, X., Tsao, C. Y., Liu, P., Lu, X., Parks, R. J., Montefiori, D. C., Ferrari, G., Pollara, J., Rao, M., Peachman, K. K., Santra, S., Letvin, N. L., Karasavvas, N., Yang, Z. Y., Dai, K., Pancera, M., Gorman, J., Wiehe, K., Nicely, N. I., Rerks-Ngarm, S., Nitayaphan, S., Kaewkungwal, J., Pitisuttithum, P., Tartaglia, J., Sinangil, F., Kim, J. H., Michael, N. L., Kepler, T. B., Kwong, P. D., Mascola, J. R., Nabel, G. J., Pinter, A., Zolla-Pazner, S. & Haynes, B. F. (2013). Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, Liao, H.X., Tsao, C. Y., Alam, S. M., Muldoon, M., Vandergrift, N., Ma, B. J., Lu, X., REV: 06/24/2018 Page 1 of 2